These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. Aiello A; Grossi A; Meschi S; Meledandri M; Vanini V; Petrone L; Casetti R; Cuzzi G; Salmi A; Altera AM; Pierelli L; Gualano G; Ascoli Bartoli T; Castilletti C; Agrati C; Girardi E; Palmieri F; Nicastri E; Di Rosa E; Goletti D Front Immunol; 2022; 13():920227. PubMed ID: 35967321 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19. Wang YC; Tsai CH; Wang YC; Yen LC; Chang YW; Sun JR; Lin TY; Chiu CH; Chao YC; Chang FY Infection; 2024 Jun; 52(3):955-983. PubMed ID: 38133713 [TBL] [Abstract][Full Text] [Related]
5. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. Gomes SMR; Brito ACS; Manfro WFP; Ribeiro-Alves M; Ribeiro RSA; da Cal MS; Lisboa VDC; Abreu DPB; Castilho LDR; Porto LCMS; Mafort TT; Lopes AJ; da Silva SAG; Dutra PML; Rodrigues LS PLoS One; 2023; 18(4):e0283983. PubMed ID: 37018291 [TBL] [Abstract][Full Text] [Related]
6. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection. Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985 [TBL] [Abstract][Full Text] [Related]
7. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Bergamaschi C; Terpos E; Rosati M; Angel M; Bear J; Stellas D; Karaliota S; Apostolakou F; Bagratuni T; Patseas D; Gumeni S; Trougakos IP; Dimopoulos MA; Felber BK; Pavlakis GN Cell Rep; 2021 Aug; 36(6):109504. PubMed ID: 34352226 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. Najafi-Fard S; Petruccioli E; Farroni C; Petrone L; Vanini V; Cuzzi G; Salmi A; Altera AMG; Navarra A; Alonzi T; Nicastri E; Palmieri F; Gualano G; Carlini V; Noonan DM; Albini A; Goletti D Front Immunol; 2022; 13():984098. PubMed ID: 36148228 [TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
13. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. Aiello A; Najafi Fard S; Petruccioli E; Petrone L; Vanini V; Farroni C; Cuzzi G; Navarra A; Gualano G; Mosti S; Pierelli L; Nicastri E; Goletti D Int J Infect Dis; 2021 May; 106():338-347. PubMed ID: 33864921 [TBL] [Abstract][Full Text] [Related]
14. Immediate Pre-Partum SARS-CoV-2 Status and Immune Profiling of Breastmilk: A Case-Control Study. Sánchez García L; Gómez-Torres N; Cabañas F; González-Sánchez R; López-Azorín M; Moral-Pumarega MT; Escuder-Vieco D; Cabañes-Alonso E; Castro I; Alba C; Rodríguez Gómez JM; Pellicer A Front Immunol; 2021; 12():720716. PubMed ID: 34381462 [TBL] [Abstract][Full Text] [Related]
15. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
16. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616 [TBL] [Abstract][Full Text] [Related]
17. Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency. Murray CE; O'Brien C; Alamin S; Phelan SH; Argue R; Kiersey R; Gardiner M; Naughton A; Keogh E; Holmes P; Naughton S; Scanlon A; Sloan A; McCrea P; Sui J; Dunne J; Conlon N Front Immunol; 2023; 14():1131604. PubMed ID: 37033955 [TBL] [Abstract][Full Text] [Related]
18. Cytokine Response Following SARS-CoV-2 Antigen Stimulation in Patients with Predominantly Antibody Deficiencies. Lucane Z; Slisere B; Gersone G; Papirte S; Gailite L; Tretjakovs P; Kurjane N Viruses; 2023 May; 15(5):. PubMed ID: 37243231 [TBL] [Abstract][Full Text] [Related]
19. Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract. Engelbrecht C; Sardinha LR; Rizzo LV Curr Eye Res; 2020 Sep; 45(9):1101-1106. PubMed ID: 31928443 [TBL] [Abstract][Full Text] [Related]
20. [Differences in immune damage between patients with severe fever with thrombocytopenia syndrome and patients with tsutsugamushi disease]. Hu L; Kong Q; Yue C; He L; Xia L; Li J Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Aug; 32(8):947-952. PubMed ID: 32912408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]